Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
2024
2023
AI and Medicines: A Year in Focus
2022
HAI and Partners Launch New SRH Project
Artificial Intelligence Act – A long awaited report surfaces
EU rushing WTO members to adopt weak waiver text
Risks and Harms from Health-related AI
Make good on access to medicine commitments HAI asks new Dutch Health Minister
2021
Transparency: Bringing the Issue to Life
Working with the European Parliament
COVID-19: European Commission gives lacklustre response to legitimate civil society concerns
European Commission is offering no meaningful solutions for equitable access
Clinical Trial Data and the Risk of Bias
Getting Hack to Reality
A Pandemic Response Lacking Moral Leadership
MPs and MEPs Call for TRIPS Waiver
Over 100 MEPs call for a TRIPS Waiver
Access to Medicines in Europe
2020
HAI’s Great Health Hack Delivers Great Ideas for Access to Meds
Europe Faces a Critical Time of Key Medicine Shortages Amidst a Pandemic
What do the next five years have in store for the European Medicines Agency?
Dutch institutions failing to register results of clinical trials
EU Must Not Miss its Chance on WHO Technology Pool
TRIPS-flexibilities in Health Crises and Beyond
HAI Follows Dutch Government Advice in Response to COVID-19
2018
What Role Can Civil Society Play in the European Regulatory Process?
Open Science for Health: Shaping the New Framework Programme
2017
EU-Mercosur Trade Agreement: A bad deal for transparency, policy coherence and access to medicines
European Commission Appoints Health Action International to HTA Network Stakeholder Pool
2016
Clinical Trial Data Transparency on Trial – EMA Under Pressure From Pharma Lawsuit
2015